Working… Menu
Trial record 1 of 1 for:    ZWI-ZW25-203
Previous Study | Return to List | Next Study

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04466891
Recruitment Status : Recruiting
First Posted : July 10, 2020
Last Update Posted : May 11, 2021
BeiGene, Ltd.
Information provided by (Responsible Party):
Zymeworks Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : January 2023